Yes, there are ongoing clinical trials exploring various approaches to target p53 in cancers. These trials include testing small molecules that reactivate mutant p53, gene therapy strategies, and combination therapies that enhance the effectiveness of existing treatments by modulating p53 pathways. The results of these trials will provide valuable insights into the potential of p53-targeted therapies in clinical practice.